MNTA
NASDAQMomenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. (MNTA) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for MNTA in the last 30 days. The most recent was published Oct 1, 2020.
Latest news
3 items- PRMomenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & JohnsonCAMBRIDGE, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion. The all-cash tender offer by Vigor Sub, Inc. (“Vigor”), a wholly owned subsidiary of Johnson & Johnson, for all outstanding shares of Momenta common stock for $52.50 per share expired at 12:00 a.m. (midnight), New York City time, at the end of the day on September 30, 2020. American Stock Transfer & Trust
- PRALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders are Encouraged to Contact the FirmNEW YORK, Sept. 17, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Varian Medical Systems, Inc. (NYSE: VAR) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Siemens Healthineers AG for $177.50 per share. To learn more about your legal rights and options, visit: https://halpersadeh.com/actions/varian-medical-systems-inc-var-stock-merger-siemens. Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Johnson & Johnson for $52.50 per share in cash. To learn more
- PRBragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Rosetta Stone, Momenta, Jernigan, and Varian on behalf of Stockholders and Encourages Investors to Contact the FirmNEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian Medical Systems, Inc. (NYSE: VAR). Additional information about each potential action can be found at the link provided. Rosetta Stone Inc. (NYSE: RST) Buyer: Cambium Learning Group On August 31, 2020, Rosetta Stone announced that it had signed an agreement to be acquired by Cambium for approximately $792 million. Pursuant to the merger agreement, Rosetta Stone stockholders will receive $30 in cash for
MNTA FAQ
6 questionsWhat is the latest news on MNTA?
Quantisnow has not tracked any new filings, ratings or press releases for MNTA in the last 30 days. The most recent wire item was published on October 1, 2020.Where does MNTA stock trade?
Momenta Pharmaceuticals, Inc. (MNTA) is listed on NASDAQ.What sector and industry is MNTA in?
Momenta Pharmaceuticals, Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Momenta Pharmaceuticals, Inc. go public?
Momenta Pharmaceuticals, Inc. (MNTA) completed its IPO in 2004.What companies are similar to MNTA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare MNTA side-by-side with any of them on Quantisnow.How can I track MNTA on Quantisnow?
Quantisnow aggregates Momenta Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNTA to receive live email and push alerts on every new disclosure.